- Home
- KZR
as 07-26-2024 4:00pm EST
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 56.2M | IPO Year: | 2018 |
| Target Price: | $4.50 | AVG Volume (30 days): | 981.9K |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.40 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.54 - $2.28 | Next Earning Date: | 08-08-2024 |
| Revenue: | $7,000,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | -65.37% | Revenue Growth (next year): | 66.67% |
Latest Kezar Life Sciences Inc. News
KZR Breaking Stock News: Dive into KZR Ticker-Specific Updates for Smart Investing
Business Wire
16 days ago
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Business Wire
2 months ago
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Business Wire
2 months ago
Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference
Business Wire
3 months ago
Kezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update
Business Wire
3 months ago
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Insider Monkey
4 months ago
13 Best Penny Stocks to Buy According to Billionaire Ken Griffin
Business Wire
4 months ago
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Business Wire
4 months ago
Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update
Compare KZR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KZR Kezar Life Sciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.